×

CellRapeutics™ Serum from Primary Biliary Cholangitis Donor (XS-0426-XU169)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product consists of serum isolated from donors afflicted with Primary Biliary Cholangitis (PBC), a chronic cholestatic liver disease. These specimens typically exhibit high titers of anti-mitochondrial antibodies and elevated alkaline phosphatase levels. The serum provides a robust model for studying autoimmune-mediated destruction of the intrahepatic bile ducts and the inflammatory cascades leading to biliary cirrhosis and hepatic fibrosis.

Specific Inquiry

  • Size:
  Add to Cart

Donor Information

  • Product Name
  • CellRapeutics™ Serum from Primary Biliary Cholangitis Donor
  • Cat. No.
  • XS-0426-XU169
  • Donor Age
  • Middle-Aged, Senior
  • Donor Health
  • Diagnosed with PBC. Serum is distinguished by high titers of anti-mitochondrial antibodies and specific markers of small bile duct autoimmune destruction and cholestasis.
  • Ethnicity
  • Predominantly Caucasian.
  • Anticoagulant
  • None (separated via centrifugation following natural coagulation).
  • Additional Donor Information
  • Each lot features serum from donors with PBC. Profiles include anti-mitochondrial antibody titers, alkaline phosphatase levels, and history of Ursodeoxycholic acid therapy.
  • Clinical Profile
  • Anti-mitochondrial antibody status, alkaline phosphatase levels, and response to Ursodeoxycholic acid.

Additional Information

  • Medication History
  • Available upon request. Includes history of Ursodeoxycholic acid, Obeticholic acid, and treatments for pruritus or associated autoimmune manifestations.
  • Formulation
  • Frozen
  • Cell Viability
  • Cell-free (no residual erythrocytes or leukocytes).
  • Mycoplasma Testing
  • Negative
  • Sterility Testing
  • Negative
  • Application
  • Drug Discovery, Immuno-oncology Research
  • Research Use Only
  • RUO
  • Quality Control
  • Each serum batch undergoes rigorous IRB-compliant screening, ensuring pathogen-free safety, consistent physicochemical properties, and standardized clinical characterization of disease-specific biomarkers to provide a reliable, high-purity biological matrix.
  • Storage
  • Store at -80°C or below for long-term stability, or at -20°C for up to 6 months, avoid repeated freeze-thaw cycles to preserve product quality.
  • Shiping
  • Dry Ice
  • Handling Notes
  • Thaw slowly on ice or at 4°C and centrifuge to remove cryoprecipitates, immediate aliquoting upon first thaw is recommended to maintain autoantibody functional integrity.
  • Warnings
  • Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.
  • Size
  • 1ML
  • Keywords
  • CellRapeutics™ Serum from Primary Biliary Cholangitis Donor, Serum, Primary Biliary Cholangitis

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Serum from Primary Biliary Cholangitis Donor (XS-0426-XU169). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.